Global Bulbospinal Muscular Atrophy Drugs Market by Product Type (Dutasteride, Leuprorelin), by End User (Specialty Clinics, Hospitals, Homecare) and Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast To 2028
Up Market Research published a new report titled “Bulbospinal Muscular Atrophy Drugs Market research report which is segmented by Product Type (Dutasteride, Leuprorelin), by End User (Specialty Clinics, Hospitals, Homecare), By Players/Companies Natera Inc., Takeda Pharmaceutical Company Limited, Pfizer Inc., Novartis AG, Salarius Pharmaceuticals Inc., Leadiant Biosciences Inc., Abbott, Boehringer Ingelheim International GmbH, F. Hoffmann-La Roche Ltd., PTC Therapeutics, Ionis Pharmaceuticals Inc., Regeneron Pharmaceuticals Inc., Novo Nordisk A/S, AstraZeneca, Catalyst Pharma”. As per the study the market is expected to grow at a CAGR of XX% in the forecast period.
Report Scope
| Report Attributes | Report Details |
| Report Title | Bulbospinal Muscular Atrophy Drugs Market Research Report |
| By Product Type | Dutasteride, Leuprorelin |
| By End User | Specialty Clinics, Hospitals, Homecare |
| By Companies | Natera Inc., Takeda Pharmaceutical Company Limited, Pfizer Inc., Novartis AG, Salarius Pharmaceuticals Inc., Leadiant Biosciences Inc., Abbott, Boehringer Ingelheim International GmbH, F. Hoffmann-La Roche Ltd., PTC Therapeutics, Ionis Pharmaceuticals Inc., Regeneron Pharmaceuticals Inc., Novo Nordisk A/S, AstraZeneca, Catalyst Pharma |
| Regions Covered | North America, Europe, APAC, Latin America, MEA |
| Base Year | 2020 |
| Historical Year | 2018 to 2019 (Data from 2010 can be provided as per availability) |
| Forecast Year | 2028 |
| Number of Pages | 213 |
| Number of Tables & Figures | 150 |
| Customization Available | Yes, the report can be customized as per your need. |
The report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can change the market dynamics of the industry. It provides an in-depth analysis of the market segments which include products, applications, and competitor analysis.
Global Bulbospinal Muscular Atrophy Drugs Market Report Segments:
The market is segmented by Product Type (Dutasteride, Leuprorelin), by End User (Specialty Clinics, Hospitals, Homecare).
Some of the companies that are profiled in this report are:
- Natera Inc.
- Takeda Pharmaceutical Company Limited
- Pfizer Inc.
- Novartis AG
- Salarius Pharmaceuticals Inc., Leadiant Biosciences Inc.
- Abbott
- Boehringer Ingelheim International GmbH
- F. Hoffmann-La Roche Ltd.
- PTC Therapeutics
- Ionis Pharmaceuticals Inc., Regeneron Pharmaceuticals Inc.
- Novo Nordisk A/S
- AstraZeneca, Catalyst Pharma
Bulbospinal Muscular Atrophy Drugs Market research report delivers a close watch on leading competitors with strategic analysis, micro and macro market trend and scenarios, pricing analysis and a holistic overview of the market situations in the forecast period. It is a professional and a detailed report focusing on primary and secondary drivers, market share, leading segments and geographical analysis. Further, key players, major collaborations, merger & acquisitions along with trending innovation and business policies are reviewed in the report.
Key Benefits for Industry Participants & Stakeholders:
- Industry drivers, restraints, and opportunities covered in the study
- Neutral perspective on the market performance
- Recent industry trends and developments
- Competitive landscape & strategies of key players
- Potential & niche segments and regions exhibiting promising growth covered
- Historical, current, and projected market size, in terms of value
- In-depth analysis of the Bulbospinal Muscular Atrophy Drugs Market
Overview of the regional outlook of the Bulbospinal Muscular Atrophy Drugs Market:
Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa (MEA). North America region is further bifurcated into countries such as U.S., and Canada. The Europe region is further categorized into U.K., France, Germany, Italy, Spain, Russia, and Rest of Europe. Asia Pacific is further segmented into China, Japan, South Korea, India, Australia, South East Asia, and Rest of Asia Pacific. Latin America region is further segmented into Brazil, Mexico, and Rest of Latin America, and the MEA region is further divided into GCC, Turkey, South Africa, and Rest of MEA.
Highlights of The Bulbospinal Muscular Atrophy Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of Bulbospinal Muscular Atrophy Drugs Market.
- Historical data and forecast.
- Estimations for the forecast period 2028.
- Developments and trends in the market.
1. Dutasteride
2. Leuprorelin
7. By End User:1. Specialty Clinics
2. Hospitals
3. Homecare
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Bulbospinal Muscular Atrophy Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2028.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
Reasons to Purchase the Bulbospinal Muscular Atrophy Drugs Market Report:
- The report includes a plethora of information such as market dynamics scenario and opportunities during the forecast period
- Segments and sub-segments include quantitative, qualitative, value (USD Million,) and volume (Units Million) data.
- Regional, sub-regional, and country level data includes the demand and supply forces along with their influence on the market.
- The competitive landscape comprises share of key players, new developments, and strategies in the last three years.
- Comprehensive companies offering products, relevant financial information, recent developments, SWOT analysis, and strategies by these players.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Bulbospinal Muscular Atrophy Drugs Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Bulbospinal Muscular Atrophy Drugs Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Bulbospinal Muscular Atrophy Drugs Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Bulbospinal Muscular Atrophy Drugs Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Bulbospinal Muscular Atrophy Drugs Market Size & Forecast, 2018-2028
4.5.1 Bulbospinal Muscular Atrophy Drugs Market Size and Y-o-Y Growth
4.5.2 Bulbospinal Muscular Atrophy Drugs Market Absolute $ Opportunity
Chapter 5 Global Bulbospinal Muscular Atrophy Drugs Market Analysis and Forecast by Product Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Product Type
5.1.2 Basis Point Share (BPS) Analysis by Product Type
5.1.3 Absolute $ Opportunity Assessment by Product Type
5.2 Bulbospinal Muscular Atrophy Drugs Market Size Forecast by Product Type
5.2.1 Dutasteride
5.2.2 Leuprorelin
5.3 Market Attractiveness Analysis by Product Type
Chapter 6 Global Bulbospinal Muscular Atrophy Drugs Market Analysis and Forecast by End User
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by End User
6.1.2 Basis Point Share (BPS) Analysis by End User
6.1.3 Absolute $ Opportunity Assessment by End User
6.2 Bulbospinal Muscular Atrophy Drugs Market Size Forecast by End User
6.2.1 Specialty Clinics
6.2.2 Hospitals
6.2.3 Homecare
6.3 Market Attractiveness Analysis by End User
Chapter 7 Global Bulbospinal Muscular Atrophy Drugs Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Bulbospinal Muscular Atrophy Drugs Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Bulbospinal Muscular Atrophy Drugs Analysis and Forecast
9.1 Introduction
9.2 North America Bulbospinal Muscular Atrophy Drugs Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Bulbospinal Muscular Atrophy Drugs Market Size Forecast by Product Type
9.6.1 Dutasteride
9.6.2 Leuprorelin
9.7 Basis Point Share (BPS) Analysis by Product Type
9.8 Absolute $ Opportunity Assessment by Product Type
9.9 Market Attractiveness Analysis by Product Type
9.10 North America Bulbospinal Muscular Atrophy Drugs Market Size Forecast by End User
9.10.1 Specialty Clinics
9.10.2 Hospitals
9.10.3 Homecare
9.11 Basis Point Share (BPS) Analysis by End User
9.12 Absolute $ Opportunity Assessment by End User
9.13 Market Attractiveness Analysis by End User
Chapter 10 Europe Bulbospinal Muscular Atrophy Drugs Analysis and Forecast
10.1 Introduction
10.2 Europe Bulbospinal Muscular Atrophy Drugs Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Bulbospinal Muscular Atrophy Drugs Market Size Forecast by Product Type
10.6.1 Dutasteride
10.6.2 Leuprorelin
10.7 Basis Point Share (BPS) Analysis by Product Type
10.8 Absolute $ Opportunity Assessment by Product Type
10.9 Market Attractiveness Analysis by Product Type
10.10 Europe Bulbospinal Muscular Atrophy Drugs Market Size Forecast by End User
10.10.1 Specialty Clinics
10.10.2 Hospitals
10.10.3 Homecare
10.11 Basis Point Share (BPS) Analysis by End User
10.12 Absolute $ Opportunity Assessment by End User
10.13 Market Attractiveness Analysis by End User
Chapter 11 Asia Pacific Bulbospinal Muscular Atrophy Drugs Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Bulbospinal Muscular Atrophy Drugs Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Bulbospinal Muscular Atrophy Drugs Market Size Forecast by Product Type
11.6.1 Dutasteride
11.6.2 Leuprorelin
11.7 Basis Point Share (BPS) Analysis by Product Type
11.8 Absolute $ Opportunity Assessment by Product Type
11.9 Market Attractiveness Analysis by Product Type
11.10 Asia Pacific Bulbospinal Muscular Atrophy Drugs Market Size Forecast by End User
11.10.1 Specialty Clinics
11.10.2 Hospitals
11.10.3 Homecare
11.11 Basis Point Share (BPS) Analysis by End User
11.12 Absolute $ Opportunity Assessment by End User
11.13 Market Attractiveness Analysis by End User
Chapter 12 Latin America Bulbospinal Muscular Atrophy Drugs Analysis and Forecast
12.1 Introduction
12.2 Latin America Bulbospinal Muscular Atrophy Drugs Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Bulbospinal Muscular Atrophy Drugs Market Size Forecast by Product Type
12.6.1 Dutasteride
12.6.2 Leuprorelin
12.7 Basis Point Share (BPS) Analysis by Product Type
12.8 Absolute $ Opportunity Assessment by Product Type
12.9 Market Attractiveness Analysis by Product Type
12.10 Latin America Bulbospinal Muscular Atrophy Drugs Market Size Forecast by End User
12.10.1 Specialty Clinics
12.10.2 Hospitals
12.10.3 Homecare
12.11 Basis Point Share (BPS) Analysis by End User
12.12 Absolute $ Opportunity Assessment by End User
12.13 Market Attractiveness Analysis by End User
Chapter 13 Middle East & Africa (MEA) Bulbospinal Muscular Atrophy Drugs Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Bulbospinal Muscular Atrophy Drugs Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Bulbospinal Muscular Atrophy Drugs Market Size Forecast by Product Type
13.6.1 Dutasteride
13.6.2 Leuprorelin
13.7 Basis Point Share (BPS) Analysis by Product Type
13.8 Absolute $ Opportunity Assessment by Product Type
13.9 Market Attractiveness Analysis by Product Type
13.10 Middle East & Africa (MEA) Bulbospinal Muscular Atrophy Drugs Market Size Forecast by End User
13.10.1 Specialty Clinics
13.10.2 Hospitals
13.10.3 Homecare
13.11 Basis Point Share (BPS) Analysis by End User
13.12 Absolute $ Opportunity Assessment by End User
13.13 Market Attractiveness Analysis by End User
Chapter 14 Competition Landscape
14.1 Bulbospinal Muscular Atrophy Drugs Market: Competitive Dashboard
14.2 Global Bulbospinal Muscular Atrophy Drugs Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Natera Inc.
14.3.2 Takeda Pharmaceutical Company Limited
14.3.3 Pfizer Inc.
14.3.4 Novartis AG
14.3.5 Salarius Pharmaceuticals Inc., Leadiant Biosciences Inc.
14.3.6 Abbott
14.3.7 Boehringer Ingelheim International GmbH
14.3.8 F. Hoffmann-La Roche Ltd.
14.3.9 PTC Therapeutics
14.3.10 Ionis Pharmaceuticals Inc., Regeneron Pharmaceuticals Inc.
14.3.11 Novo Nordisk A/S
14.3.12 AstraZeneca, Catalyst Pharma
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Bulbospinal Muscular Atrophy Drugs Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Bulbospinal Muscular Atrophy Drugs Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Bulbospinal Muscular Atrophy Drugs Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Bulbospinal Muscular Atrophy Drugs Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Bulbospinal Muscular Atrophy Drugs Market Size & Forecast, 2018-2028
4.5.1 Bulbospinal Muscular Atrophy Drugs Market Size and Y-o-Y Growth
4.5.2 Bulbospinal Muscular Atrophy Drugs Market Absolute $ Opportunity
Chapter 5 Global Bulbospinal Muscular Atrophy Drugs Market Analysis and Forecast by Product Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Product Type
5.1.2 Basis Point Share (BPS) Analysis by Product Type
5.1.3 Absolute $ Opportunity Assessment by Product Type
5.2 Bulbospinal Muscular Atrophy Drugs Market Size Forecast by Product Type
5.2.1 Dutasteride
5.2.2 Leuprorelin
5.3 Market Attractiveness Analysis by Product Type
Chapter 6 Global Bulbospinal Muscular Atrophy Drugs Market Analysis and Forecast by End User
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by End User
6.1.2 Basis Point Share (BPS) Analysis by End User
6.1.3 Absolute $ Opportunity Assessment by End User
6.2 Bulbospinal Muscular Atrophy Drugs Market Size Forecast by End User
6.2.1 Specialty Clinics
6.2.2 Hospitals
6.2.3 Homecare
6.3 Market Attractiveness Analysis by End User
Chapter 7 Global Bulbospinal Muscular Atrophy Drugs Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Bulbospinal Muscular Atrophy Drugs Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Bulbospinal Muscular Atrophy Drugs Analysis and Forecast
9.1 Introduction
9.2 North America Bulbospinal Muscular Atrophy Drugs Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Bulbospinal Muscular Atrophy Drugs Market Size Forecast by Product Type
9.6.1 Dutasteride
9.6.2 Leuprorelin
9.7 Basis Point Share (BPS) Analysis by Product Type
9.8 Absolute $ Opportunity Assessment by Product Type
9.9 Market Attractiveness Analysis by Product Type
9.10 North America Bulbospinal Muscular Atrophy Drugs Market Size Forecast by End User
9.10.1 Specialty Clinics
9.10.2 Hospitals
9.10.3 Homecare
9.11 Basis Point Share (BPS) Analysis by End User
9.12 Absolute $ Opportunity Assessment by End User
9.13 Market Attractiveness Analysis by End User
Chapter 10 Europe Bulbospinal Muscular Atrophy Drugs Analysis and Forecast
10.1 Introduction
10.2 Europe Bulbospinal Muscular Atrophy Drugs Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Bulbospinal Muscular Atrophy Drugs Market Size Forecast by Product Type
10.6.1 Dutasteride
10.6.2 Leuprorelin
10.7 Basis Point Share (BPS) Analysis by Product Type
10.8 Absolute $ Opportunity Assessment by Product Type
10.9 Market Attractiveness Analysis by Product Type
10.10 Europe Bulbospinal Muscular Atrophy Drugs Market Size Forecast by End User
10.10.1 Specialty Clinics
10.10.2 Hospitals
10.10.3 Homecare
10.11 Basis Point Share (BPS) Analysis by End User
10.12 Absolute $ Opportunity Assessment by End User
10.13 Market Attractiveness Analysis by End User
Chapter 11 Asia Pacific Bulbospinal Muscular Atrophy Drugs Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Bulbospinal Muscular Atrophy Drugs Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Bulbospinal Muscular Atrophy Drugs Market Size Forecast by Product Type
11.6.1 Dutasteride
11.6.2 Leuprorelin
11.7 Basis Point Share (BPS) Analysis by Product Type
11.8 Absolute $ Opportunity Assessment by Product Type
11.9 Market Attractiveness Analysis by Product Type
11.10 Asia Pacific Bulbospinal Muscular Atrophy Drugs Market Size Forecast by End User
11.10.1 Specialty Clinics
11.10.2 Hospitals
11.10.3 Homecare
11.11 Basis Point Share (BPS) Analysis by End User
11.12 Absolute $ Opportunity Assessment by End User
11.13 Market Attractiveness Analysis by End User
Chapter 12 Latin America Bulbospinal Muscular Atrophy Drugs Analysis and Forecast
12.1 Introduction
12.2 Latin America Bulbospinal Muscular Atrophy Drugs Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Bulbospinal Muscular Atrophy Drugs Market Size Forecast by Product Type
12.6.1 Dutasteride
12.6.2 Leuprorelin
12.7 Basis Point Share (BPS) Analysis by Product Type
12.8 Absolute $ Opportunity Assessment by Product Type
12.9 Market Attractiveness Analysis by Product Type
12.10 Latin America Bulbospinal Muscular Atrophy Drugs Market Size Forecast by End User
12.10.1 Specialty Clinics
12.10.2 Hospitals
12.10.3 Homecare
12.11 Basis Point Share (BPS) Analysis by End User
12.12 Absolute $ Opportunity Assessment by End User
12.13 Market Attractiveness Analysis by End User
Chapter 13 Middle East & Africa (MEA) Bulbospinal Muscular Atrophy Drugs Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Bulbospinal Muscular Atrophy Drugs Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Bulbospinal Muscular Atrophy Drugs Market Size Forecast by Product Type
13.6.1 Dutasteride
13.6.2 Leuprorelin
13.7 Basis Point Share (BPS) Analysis by Product Type
13.8 Absolute $ Opportunity Assessment by Product Type
13.9 Market Attractiveness Analysis by Product Type
13.10 Middle East & Africa (MEA) Bulbospinal Muscular Atrophy Drugs Market Size Forecast by End User
13.10.1 Specialty Clinics
13.10.2 Hospitals
13.10.3 Homecare
13.11 Basis Point Share (BPS) Analysis by End User
13.12 Absolute $ Opportunity Assessment by End User
13.13 Market Attractiveness Analysis by End User
Chapter 14 Competition Landscape
14.1 Bulbospinal Muscular Atrophy Drugs Market: Competitive Dashboard
14.2 Global Bulbospinal Muscular Atrophy Drugs Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Natera Inc.
14.3.2 Takeda Pharmaceutical Company Limited
14.3.3 Pfizer Inc.
14.3.4 Novartis AG
14.3.5 Salarius Pharmaceuticals Inc., Leadiant Biosciences Inc.
14.3.6 Abbott
14.3.7 Boehringer Ingelheim International GmbH
14.3.8 F. Hoffmann-La Roche Ltd.
14.3.9 PTC Therapeutics
14.3.10 Ionis Pharmaceuticals Inc., Regeneron Pharmaceuticals Inc.
14.3.11 Novo Nordisk A/S
14.3.12 AstraZeneca, Catalyst Pharma
Segments Covered in the Report
The global Bulbospinal Muscular Atrophy Drugs market has been segmented based on
By Product Type
The global Bulbospinal Muscular Atrophy Drugs market has been segmented based on
By Product Type
- Dutasteride
- Leuprorelin
- Specialty Clinics
- Hospitals
- Homecare
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
- Natera Inc.
- Takeda Pharmaceutical Company Limited
- Pfizer Inc.
- Novartis AG
- Salarius Pharmaceuticals Inc., Leadiant Biosciences Inc.
- Abbott
- Boehringer Ingelheim International GmbH
- F. Hoffmann-La Roche Ltd.
- PTC Therapeutics
- Ionis Pharmaceuticals Inc., Regeneron Pharmaceuticals Inc.
- Novo Nordisk A/S
- AstraZeneca, Catalyst Pharma
Our Clients
Related Reports
Some other reports from this category!
